<DOC>
	<DOCNO>NCT01424033</DOCNO>
	<brief_summary>The first objective protocol ass tolerability safety N-acetylcysteine ( NAC ) patient connective tissue disease relate interstitial lung disease ( CTD-ILD ) .</brief_summary>
	<brief_title>A Clinical Trial CTD-ILD Treatment</brief_title>
	<detailed_description>The investigator assess tolerability safety schedule interval via standard care physical exam finding , monitor complete blood count , serum chemistry , pulmonary function test , along patient report medication intolerance change symptom dyspnea .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Inclusion : 1 . Subject give voluntary write informed consent participate study . 2 . Subject diagnose connective tissue disease associate interstitial lung disease confirm computed tomography lung along symptom cough and/or shortness breath . 3 . Males females age great 18 year time screen . 4 . Females childbearing potential must willing use reliable form medically acceptable contraception negative pregnancy test confirm baseline start NAC per standard care . Women surgically sterile postmenopausal least two year consider childbearing potential . Exclusion : 1 . History severe chronic kidney disease define glomerular filtration rate le 30 . 2 . Hemoglobin concentration le 70 % low limit normal range time screen . 3 . Moderate severe hepatic impairment , i.e. , ChildPugh Class B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Interstitial lung disease</keyword>
	<keyword>Connective tissue disease</keyword>
	<keyword>Scleroderma</keyword>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Sjogren 's syndrome</keyword>
	<keyword>Mixed connective tissue disease</keyword>
	<keyword>Dermatomyositis</keyword>
	<keyword>Polymyositis</keyword>
	<keyword>Systemic lupus erythematosis</keyword>
</DOC>